Status: Not yet recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.
Participants needed: 130
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Jun 23, 2026Locations: 37
Eligibility criteria
Have a clinical diagnosis of T2D based on the World Health Organization (WHO) cl... [+4]
Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gesta... [+6]